Atlas Trials

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Clinical trial NCT05665348 · COMPLETED

Trial details

NCT number
NCT05665348
Sponsor
Federation Francophone de Cancerologie Digestive
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
HCC - Hepatocellular CarcinomaMetastatic CancerMetastatic Tumor
Start date
2023-03-09
Primary completion
2025-05-12
Enrollment
229

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.